Depth bar: Listed UK CDMO. Regulatory/labour items cited with sources; no invented outcomes. Bill bands [~].

1. Company overview & snapshot

1.1 Legal identity & corporate structure

Windlas Biotech Limited is a listed Indian pharmaceutical CDMO / formulations company (BSE/NSE ticker commonly WINDLAS). Promoter family: Hitesh Windlass (Managing Director), Manoj Kumar Windlass (Joint MD), with Ashok Windlas appearing in press as full-time director. Komal Gupta is CEO & CFO. Registered/plant geography is Dehradun-focused (Selaqui Pharma City and Mohabewala Industrial Area plants). Annual Report FY2024-25 on BSE/company site; consolidated turnover cited around ₹7,779 million (~₹778 Cr) with PAT ~₹610 million [~].

Multiple plant numbers (Plant-1 nutraceuticals through Plant-5 injectables and Plant-6 OSD brownfield) sit under one listed entity but may have separate UPCL HT accounts — confirm. Share buyback (May 2026, ~₹47 Cr) increased promoter holding narrative to ~63% — capital-return mode coexists with plant expansion.

1.2 What they make & where money comes from

Business lines: domestic CDMO, trade generics, institutional and exports. Dosage forms: tablets, capsules, syrups, sachets; newest capability small-volume parenteral injectables (ampoules, vials, lyophilised). Plant-4 (ex Windlas Healthcare) carries EU-GMP / SAHPRA / Philippines FDA type accreditations; Plant-5 is the injectable facility. Capacity expansion of Plant-2 and Plant-6 (Selaqui brownfield land purchase ~₹13+ Cr in call commentary; broader FY25 injectables/capex ~₹72 Cr in lead framing). Revenue growth depends on utilisation of new lines — energy intensity rises with HVAC class before revenue fully catches up.

1.3 Plants, addresses & footprint

Pilot pick: Selaqui Plant-6 / Pharma City cluster or highest-bill Mohabewala OSD plant — whichever finance confirms ≥₹30L. Do not assume one meter covers both industrial areas.

1.4 Leadership & CRM map

Path: Engineering → Plant → CFO for opex. Digital QMS mentions in AR imply IT maturity — still start with read-only meter export, not full historian dreams.

1.5 Recent news (24 months) & timing for Stamped

• Injectables revenue ramp commentary FY25; Plant-6 acquisition/retrofit ongoing.
• Feb 10 2026: Uttarakhand FDA halted codeine-containing cough syrup production at a Windlas unit and suspended that drug licence after inspection found quality irregularities (PTI / The Week; Ashok Windlas declined immediate comment). This is a product-licence action, not a company shutdown — still material for tone (avoid flippancy; do not open outreach on this topic).
• May 18 2026: Temporary labour-unrest disruption at Mohabewala sites; restored same evening; company said no material financial impact; buyback also announced same day.
• Timing: after injectables/Plant-6 spend — sell operational bill proof, not more capex gadgets. Keep regulatory risk out of the sales narrative unless they raise it.

2. Energy profile

DISCOM / supply: UPCL for Dehradun / Selaqui / Mohabewala HT consumers. Confirm tariff category and multi-feeder layout.

2.1 Bill band, tariff & demand

No public plant bills. Multi-plant WHO-GMP pharma with HVAC + new injectables typically implies ₹40 lakh–₹1.5 Cr+/month on large feeders [~] — must verify. Ask for demand spikes during HVAC validation, sterilisation cycles, and lyophiliser runs.

2.2 Generation, fuel & renewables

AR annexure on energy conservation exists (Rule 8(3)) — extract specific measures on call. Solar/captive not strongly marketed in public snippets reviewed. DG and boilers presumed.

2.3 EnMS, PAT, ISO, BRSR

WHO-GMP, plant-specific ISO (e.g. Plant-1 ISO 22000), EcoVadis/Sedex mentions for some plants. Listed BRSR applicability depends on thresholds — check latest AR. ISO 50001 unknown. Digital QMS ≠ energy M&V.

2.4 Likely ₹ leak categories (hypothesis)

1. HVAC class restart after audits / shutdowns
2. Injectables clean utilities overlap with OSD peaks across Mohabewala vs Selaqui
3. Compressed air weekends
4. Lyophiliser / autoclave coincident starts
5. PF on large packaged HVAC
6. Plant-6 commissioning phantom base load

3. Operations, equipment & digital stack

3.1 Process flow & critical loads

OSD path standard; SVP path: compounding → filtration → filling → lyophilisation → inspection. Utilities: HVAC, CA, PW/WFI, steam, chillers. Critical constraint: validated environments — no recipe or differential-pressure games.

3.2 Shifts, seasonality, production pattern

Multi-shift; regulatory audits freeze changes; export batch campaigns. Normalise pilots to batch counts / line-hours.

3.3 Automation, metering, SCADA/EMS/DCS

Digital QMS/analytics referenced in AR. Path A/B both possible; Path B safer until OT review. Explicit: no PLC writes, no MES changes.

3.4 Capex / tech projects affecting energy

Plant-2 extension, Plant-6, injectables — baselines unstable through ramp. Sell post-capex verification.

4. Stamped Energy fit analysis

4.1 ICP scorecard

Pass geography/vertical/revenue. Bill unknown likely pass. Decision speed medium-high (promoter + engaged CEO). Data maturity medium-high. Accessibility good via engineering LinkedIn.

4.2 Fit score rationale

9/10 — expansion-driven utility load, named HOD Engineering, listed discipline for M&V. Score risk: FDA/codeine attention and labour noise may distract; EMS from integrators.

4.3 Wedge (parser-critical)

The strongest wedge is: post–injectables and Plant-6 ramp, Pharma City vs Mohabewala HVAC/compressor starts still stacking into UPCL MD without feeder-level ₹ owners — verify with evidence in 90 days, read-only.

4.4 Objections & competitors

EMS integrator, internal projects cell, ISO consultant, “we buy solar next.” Stay on bill verification. If they raise codeine FDA: acknowledge seriousness, stay in utilities lane, do not opine on product quality.

4.5 Pilot design

One UPCL feeder at Selaqui or Mohabewala. Success: owned MD/idle-air action with invoice evidence. Kill: bill low, QA blocks, regulatory firefight absorbs management.

5. Before you reach out

5.1 Discovery checklist

• Legal entity / plant / UPCL account match
• Bill band & CMD
• Which plants share demand
• HVAC vs process share of kWh
• Historian export policy
• Solar/DG
• Capsule of Plant-6 status (commissioning %)
• Approver for 90-day fee
• Any freeze from FDA actions on unrelated lines

5.2 Do not lead with

• Codeine / FDA story
• Carbon accounting
• Guaranteed percent without bills
• Combining Selaqui+Mohabewala in one uncontrolled scope

5.3 Opening hooks

“After Plant-6 and injectables, which utility feeder still refuses to reconcile to the UPCL invoice? We assign ₹ owners read-only and verify in 90 days.”

6. Risks, flags, controversies & sources

6.1 Integrity / controversy / regulatory (search explicitly)

Search terms: Windlas Biotech FDA codeine; Windlas labour unrest; Windlas NGT PCB; Windlas lawsuit scam GST raid.

6.2 Data quality flags

• Multi-plant UPCL ambiguity
• Email inference
• Plant numbering vs commercial names
• “Windlass” vs “Windlas” spelling in press

6.3 Sources consulted

• https://windlas.com/facilities/ · management-team-information
• BSE AR FY25 filing PDFs
• Economic Times directors’ report page
• The Week PTI Feb 10 2026 codeine story
• Business Upturn / ScanX / ainvest May 2026 labour notes
• LinkedIn: Nawab Ali, Hitesh Windlass, Komal Gupta, Manish Chittoria
• Lead: leads/uttarakhand/lead-research-uk-gap-verticals-2026-07.md

Extended call-prep narrative (Stamped field use)

B1. First 20 minutes of discovery

Open with process respect, not software. Confirm legal entity on the invoice, DISCOM name, and who owns the largest feeder MD event in the last 90 days. Ask for two invoices and one production calendar export before any platform demo. If the champion cannot produce bills within a week, treat the opportunity as stalled — Bill Verification Program without invoices is theatre. Record whether Path A (historian/meter export) or Path B (CSV) is realistic given OT policy. Confirm the economic buyer who can approve a Rs 2–5 lakh [~] fixed 90-day fee without a full ERP tender.

B2. Prescription card discipline

Every recommendation must name: event, owner, due date, expected rupee line on the DISCOM invoice, operational constraint, and evidence of execution. Cards without owners are deleted. Cap weekly cards at five so plant teams are not flooded. Prefer MD sequencing and idle-hold cuts before exotic tariff products. Never propose changing validated recipe, membrane current, sterile pressure, or Tempcore quench parameters. If quality or safety forbids a schedule change, mark the lever as blocked and move on — credibility beats aggressive savings claims.

B3. Verifying savings without gaming

A lower bill alone is not success if tonnes, pairs, or batches fell. Normalise against a production proxy agreed in week 1. Document holidays, forced outages, new-line commissioning, captive/solar settlement changes, and weather-sensitive HVAC. Keep a decision ledger shared with the plant: recommendation, owner, status, expected vs observed invoice delta. Present kill or expand at day 90 with the same ledger — this is how Stamped differs from audit PDFs that never close.

B4. Competitive and incumbent handling

If the site has EMS/SCADA/BMS, OEM analytics, ISO consultants, or solar EPCs, congratulate the spend and ask what residual bill lines still surprise them monthly. Position Stamped as the closure layer: rupee assignments and invoice reconciliation. Refuse head-to-head dashboard bake-offs. If Gujarat, Panipat, or Noida corporate IT appears, keep plant electrical as the proof owner and let corporate rubber-stamp after a verified bill line — not before.

B5. Geographic and cluster logistics

Batch 3 spans Mandi Gobindgarh, Paonta/Derabassi/Rajpura, Ghaziabad/Muzaffarnagar, and Kanpur–Unnao. Plan field days by corridor. Carry printed one-pagers: Fit score, DISCOM hypothesis, strongest wedge sentence, and two discovery questions. After each visit, update extras field intel — especially corrected phones, electrical names, and whether the bill cleared Rs 30 lakh/month.

B6. Messaging hygiene for this batch

Owner-operated steel/leather accounts tolerate Hindi-friendly WhatsApp and short calls. Listed pharma/chemical accounts prefer email plus LinkedIn with technical depth. Never open with controversies (GST/Excise history, EuGMP observations, rating actions) — those are internal briefings only. Always name DISCOM early in research-backed prep sheets so call-prep UI can render correctly.

6.4 Evidence discipline

Treat FDA action as narrowly scoped unless court/FDA expands it. Do not use it as leverage. Keep Stamped conversation on electricity invoice ownership and read-only OT boundaries.

7. Extended call playbook & multi-plant Dehradun model (Windlas)

7.1 Selaqui vs Mohabewala — two industrial geographies, one listed P&L

Windlas’s public footprint spans Pharma City Selaqui (Plot 39 / Plant-6 brownfield story) and the older Mohabewala industrial area. Labour disclosure language specifically referenced Mohabewala disruption on 18 May 2026. Injectables Plant-5 and Plant-4 EU-facing quality systems may not share meters with Plant-6 commissioning loads. The first CRM mistake is to speak as if Dehradun plant is singular. The second is to promise campus-wide savings before UPCL consumer numbers are listed. Nawab Ali as HOD Engineering is the meta-owner who can draw that map; Manish Chittoria is a likely meter-level ally; Komal Gupta (CEO/CFO) is the person who can clear bill-sharing and opex fee once engineering agrees the problem is real.

7.2 Handling the Feb 2026 FDA/codeine action in conversation

PTI reporting states Uttarakhand FDA stopped codeine-containing cough syrup production and suspended that drug licence after inspection findings. Ashok Windlas declined immediate comment in press. For Stamped: do not open on this; if raised, acknowledge it is a serious product-quality/regulatory matter outside our scope; explicitly separate utilities electricity work from any product investigation; never imply the whole company is under shutdown — public reporting is product-licence scoped. If management is in firefight mode, park the pilot rather than force a meeting.

7.3 Injectables and lyophilisation energy fingerprint

SVP plants add autoclaves, lyophilisers, grade HVAC, and high-reliability clean utilities. Their MD signature differs from OSD compression suites. A 90-day pilot on an OSD feeder will not prove injectable economics (and vice versa). Pick one. Plant-6 retrofit of OSD next-gen claims in annual-report language means commissioning phantom loads — normalise carefully or wait until Production declares commercial batches stable.

7.4 Capex absorption and CFO conversation

FY25 call commentary referenced meaningful cash outflow for Selaqui land and Plant-2 extension. A CEO/CFO who just financed expansion and completed a buyback will reject vague digital transformation. Lead with: one feeder, fixed 90-day fee, kill criteria, invoice proof. Offer to use their existing digital QMS only as context — not as the product category Stamped competes in.

7.5 Expanded discovery questions

1. List of UPCL consumer numbers by plant number.
2. Which account exceeds ₹30L most months?
3. HVAC share of kWh estimate?
4. Plant-6 status (percent commissioned)?
5. Injectables utilising night lyophilisation?
6. Digital QMS vs energy tags — same OT network?
7. Buyback finished — capex freeze or still open?
8. Who signs verification fee — Komal or Hitesh?
9. Any freeze from FDA on data visitors?
10. EcoVadis data — who owns environmental metrics?
11. Preferred kill criteria language?
12. Mohabewala vs Selaqui which recovers faster after unrest days?

7.6 Field routing tip

If day-tripping Haridwar Akums, Selaqui is a logical second day with HAB/NATCO cluster — but keep Windlas messaging unique (Plant-6 / injectables), not copy-paste Haridwar HVAC text. Re-verify Nawab Ali title and email pattern before send.

8. Pilot economics, stakeholder map & objection library (Windlas)

Windlas is listed, promoter-influenced, and mid-sized relative to Akums — which often means faster engineering access but stricter CFO numeracy after a capex and buyback year. Price the 90-Day Bill Verification as a fixed opex line with kill criteria, not a perpetual SaaS landing. Choose either Selaqui Plant-6/Pharma City or Mohabewala’s largest HT account; never both in week one. Success metric: one owned action with invoice evidence normalised to batches or line-hours. Kill if bill gate fails, FDA/product investigation consumes leadership capacity, or OT access is refused beyond CSV.

Stakeholder map: Nawab Ali (technical map) → electrical engineer on meter details → Plant Head of chosen node → Komal Gupta for fee and bill sharing → Hitesh Windlass if technical strategy sponsorship is needed for multi-plant expansion. Manoj Windlass matters when CDMO commercial commitments constrain production schedule changes — involve him before recommending start delays that risk customer OTIF.

Objection library: “We have digital QMS and analytics” → quality analytics are not DISCOM reconciliation. “Injectables are new; baselines are unstable” → then wait for stable commercial batches or pick OSD. “Labour unrest was statewide” → agree; still need post-event MD ownership. “ICRA rating means we are fine” → credit rating is not feeder attribution. “Ashok Windlas will handle media” → stay out of product regulatory commentary entirely.

Process nuances: lyophiliser cycles can dominate night MD; autoclave and clean steam create pulse loads; OSD compression is flatter but AHU-heavy. Ask which pattern matches the chosen meter. Plant-2 extension machines inserted mid-ramp can create false year-on-year SEC comparisons — use same-quarter production context. EcoVadis/Sedex for Plant-4 is a customer compliance asset; do not pitch ESG scoring tools.

Gaps to close: verified emails; UPCL consumer list; furnace/boiler fuel mix; solar; named BMS; exact status of Plant-6 usable state; whether cough-syrup line share utilities with target feeder (if yes, note freeze risk); secondary LinkedIn for Plant Head Selaqui. Re-read AR energy annexure before the first CFO call for any quantified conservation claims the company already made publicly.

9. Ninety-day week-by-week operating plan (Windlas)

Week 0 (pre-kickoff): Confirm legal entity on the chosen UPCL bill, redacted bill share under NDA if required, and a single named Engineering owner (Nawab Ali or delegate). Freeze the pilot boundary in writing: plant number, consumer number, and which utilities are in/out. Explicitly document that Stamped will not write to PLC, BMS setpoints, or Batch Records. If Plant-6 is still in unstable commissioning, either wait or select Mohabewala OSD with stable commercial batches.

Weeks 1–2 (baseline): Ingest two to six bills; build a tariff-component table (energy, demand, PF/incentive, taxes). Overlay 15-minute demand with production batches, HVAC validation events, and any lyophiliser or autoclave cycles if on the same meter. Interview Electrical and Production for the three “worst MD days” story. Produce a one-page baseline memo: what is controllable vs sacred.

Weeks 3–6 (prescription cadence): Issue weekly ranked cards — typically MD sequencing, idle AHUs/air, weekend setpoints, and PF drift. Each card has owner, due date, operational constraint, expected invoice component, and evidence required (photo of setpoint sheet, SCADA screenshot read-only, or shift log). Hold a 30-minute weekly stand-up with Engineering; escalate to Komal Gupta only if fee/bill access blocks appear.

Weeks 7–10 (verification): Compare normalised indicators and invoice lines. Separate effects of volume change from operational change. If buyback/capex narratives dominate management attention, keep the report ruthlessly short: three slides max — baseline, actions taken, invoice delta.

Weeks 11–12 (decision): Either kill with learning documented, renew/expand to second feeder, or pause if product regulatory attention expands. Write a handover note that QA can file: no validated state was altered by Stamped software.

Security appendix: preferred interfaces are historian CSV, energy meter gateway export, or supervised read-only sessions. Retention window 90 days unless they request longer. Access roles limited to named Stamped engineers. No remote control credentials.

Normalisation appendix: choose denominator (million tablets, batches, or sterile lot-hours) before week 2 ends. Record weather if HVAC-dominated. Record any labour holiday or unrest day as excluded or tagged. Never publish a percentage to management without the denominator story.